Business
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc..
About this update from Fifty 1 Labs Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.\r\n \r\n \r\n\r\n\r\nFifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.\r\nStrategic Acquisition Bolsters AI-Driven Healthcare Innovation, Positioning Fifty 1 Labs as a Leader in Clinical Data Analytics\r\n\r\n\r\n\r\n\r\n\r\nVANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs Inc. (OTC: FITY), a leader in AI-powered healthcare and biotechnology solutions, is excited to announce the signing of a Letter of Intent (LOI) to acquire BioSpark AI Technologies Inc., a Vancouver-based innovator specializing in patented artificial intelligence systems for clinical data extraction, structuring, and real-time analysis. This strategic move builds on a successful history of collaboration between the two companies, reinforcing Fifty 1 Labs' commitment to advancing therapeutic development and functional medicine through cutting-edge AI technology. The LOI outlines Fifty 1 Labs' intent to acquire 100% of BioSpark's outstanding equity interests, including all assets, its proprietary large language model (LLM) ensemble technology, and key intellectual property, such as United States Patent Application Publication No. US 20250029734 A1. The proposed transaction includes a contingent payment of twenty-five million common shares, payable upon BioSpark achieving a revenue-based valuation milestone of US$25,000,000 (determined by multiplying annualized recurring revenue by 10x and certified by an independent third-party valuation firm mutually agreed upon by both parties), subject to the terms and conditions of a definitive Stock Purchase Agreement. This acquisition aligns with Fifty 1 Labs' focus on delivering transformative AI solutions that drive value for shareholders and enhance patient outcomes. Fifty 1 Labs and BioSpark have a proven track record of collaboration. As previously announced on OTC Markets, their strategic partnership through Fifty 1 Labs' subsidiary, Fifty1 AI Labs, has driven breakthroughs in drug repurposing by leveraging BioSpark's advanced AI tools to identify new therapeutic applications for existing compounds. Most recently, this collaboration unlocked over 2,000 real-world treatment pathways, accelerating innovation in functional medicine by processing clinic...